厄洛替尼维持治疗晚期非小细胞肺癌的随机、安慰剂对照研究中EGFR和KRAS的前瞻性分子标记分析

{"title":"厄洛替尼维持治疗晚期非小细胞肺癌的随机、安慰剂对照研究中EGFR和KRAS的前瞻性分子标记分析","authors":"A. Tsao","doi":"10.1016/S0084-3873(12)00207-6","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23907,"journal":{"name":"Yearbook of Medicine","volume":"45 1","pages":"146-147"},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer\",\"authors\":\"A. Tsao\",\"doi\":\"10.1016/S0084-3873(12)00207-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23907,\"journal\":{\"name\":\"Yearbook of Medicine\",\"volume\":\"45 1\",\"pages\":\"146-147\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Yearbook of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/S0084-3873(12)00207-6\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Yearbook of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/S0084-3873(12)00207-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}